ReviewFrontiers in pharmacology2026
Novel biopharmaceutical strategies: Fc-fusion protein technology.
Review in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Therapeutic proteins represent pivotal interventions for diverse pathologies but face inherent limitations, including a short serum half-life and suboptimal stability. Fc-fusion protein technology, an innovative biopharmaceutical approach, conjugates functional protein domains to the IgG Fc fragment via engineered linkers. By exploiting FcRn-mediated recycling and enhanced thermodynamic stability, this strategy extends the circulatory half-life. Concurrently, interactions with FcγRs and complement component 1q (C1q) confer Fc-fusion proteins immunomodulatory functions, for example, antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). Recent clinical approvals of novel Fc-fusion biologics underscore the translational viability of Fc-fusion proteins. With ongoing innovations in artificial intelligence-guided design and engineered Fc scaffolds, Fc-fusion technology is positioned to dominate next-generation biotherapeutics. Notwithstanding advantages in pharmacokinetics, challenges such as target-mediated drug disposition (TMDD) and FcRn binding interference still need to be addressed. This study systematically evaluates the current status of Fc-fusion protein drugs and recent engineering advancements to enhance the application of Fc-fusion proteins in drug development.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.